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Abstract 1-Trichloromethyl-1,2,3,4-tetrahydro-b-carbo-
line (TaClo) is neurotoxic when administered to the brain
and alters motor behaviour following intraperitoneal
administration. We have assessed the long-term effects of
oral TaClo administration on nocturnal motor behaviour in
rats. Two groups of rats received TaClo orally at a dose of
either 0.2 or 0.4 mg/kg twice daily for 7 weeks. The con-
trol group was given saline. No change in locomotor
activity was observed 4–9 days after the end of the 7-week
administration of TaClo. In addition, the spontaneous
motor activity was altered dose-dependently 9 months after
oral TaClo administration, with an increase in the low-dose
TaClo group and a decrease in the high-dose group. Oral
administration of TaClo in rats may be useful in investi-
gating the hypothesis that in Parkinson’s disease, an
unknown pathogenic factor crossing the intestinal mucosa
barrier can induce neurodegenerative processes eventually
affecting the entire brain.
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Introduction
Since the discovery that the neurotoxin 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine(MPTP)caninduceparkinsonian
symptoms in primates including man (Burns et al. 1983;
Davis et al. 1979) it has been suggested that environmental
toxins may play a role in the aetiology and pathogenesis of
Parkinson’s disease. The search for structural analogues of
MPTP in the environment has identiﬁed several compounds
such as herbicides (e.g. paraquat), alkaloids (e.g. 1,2,3,4-
tetrahydroisoquinolines) and b-carbolines. The neurotoxin
1-trichloromethyl-1,2,3,4-tetrahydro-b-carboline (TaClo)
belongs to the group of b-carbolines and bears striking
similarities to MPTP, a neurotoxin that is widely being used
toproducean animal model ofParkinson’sdisease. TaClo is
readily formed under physiological conditions from the
biogenic amine tryptamine (Ta) and trichloroacetaldehyde
(chloral, Clo; Bringmann and Hille 1990). Chloral can be
formed in vivo following exposure to the industrial solvent
trichloroethylene (TRI). An association between the expo-
sure to trichloroethylene and Parkinson’s disease in humans
has been observed (Kochen et al. 2003).
Behavioural consequences of TaClo administration have
beendemonstrated(Sontagetal.1995).Chronictreatmentof
rats with TaClo induced an acute behavioural supersensitiv-
ity to the dopaminergic agonist apomorphine. This super-
sensitivity is not permanent and is later replaced by reduced
motoractivitywhenTaCloiscompletelymetabolized(Heim
and Sontag 1997). These ﬁndings suggest a TaClo-induced
progressive degeneration of the dopaminergic system which
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The neurodegenerative process underlying Parkinson’s
disease involves not only neurons in the central nervous
system but also in the enteric and peripheral nervous sys-
tems. It has been suggested that an unidentiﬁed pathogenic
factor enters the enteric nervous system and is then retro-
gradely transferred to the central nervous system where it
induces the characteristic patterns of neurodegeneration in
Parkinson’s disease (Braak et al. 2003). This factor might
cross the mucosal barrier of the intestine and could then be
incorporated into the axon terminal of the vagus nerve and
transported in a retrograde manner to the vagus nucleus.
The question arises whether TaClo could be such an
unknown pathogenetic factor.
TaClo is neurotoxic when administered to the brain
and alters motor behaviour following intraperitoneal
administration. The hypothesis by Braak et al. (2003)
suggests that TaClo may exert its neurotoxic effects by
crossing the mucosal barrier. We have therefore assessed
the effects of oral TaClo administration on motor
behaviour in rats.
Materials and methods
Twenty-seven male Wistar rats aged three to 4 months
were used. The animals were kept on a 12:12 h light/dark
circle (room temperature 21C, humidity 55%). The rats
were divided in three groups. The two TaClo groups
received TaClo diluted in saline at a dose of 0.2 mg/kg
(N = 9) or 0.4 mg/kg (N = 8) twice daily for 7 weeks.
The control animals (N = 10) were given saline twice
daily for 7 weeks. Both TaClo and saline were adminis-
tered orally at about 11 a.m. and 5 p.m.
In order to assess the acute effects of TaClo adminis-
tration, the rats’ spontaneous motor activity was measured
for 1 h between 8 and 12 a.m. Nine months after TaClo
or saline administration, the spontaneous motor activity of
all rats was recorded during the whole night. Motor
activity was automatically measured using an Autotrack
System (Columbus Instruments, Columbus OH, USA).
The following parameters were measured using the
Autotrack System: (1) distance travelled, i.e. the total
distance (in cm) a rat walked during the recording; (2)
stereotype time, i.e. the time (in sec) a rat spent with
movements covering less than 4.8 cm; and (3) burst of
stereotype movements, i.e. the total number of move-
ments covering less than 4.8 cm. Data were recorded over
1-h intervals.
The rats were placed in the Autotrack System at 1 p.m.
in order to allow them to adapt to the experimental envi-
ronment. The recording of motor activity started at 8 p.m.
and lasted for 10 h. The light was turned off at 6 p.m. and
turned on at 6 a.m. During the testing the rats had free
access to food and water.
The comparison of the rats’ activity between the
groups was performed both for the total of 10 h and for
each hour separately. Statistical analysis was performed
using analysis of variance and the Student–Newman–
Keuls test. For statistical analysis an alpha level of 0.05
was applied. All statistical analyses were carried out using
the Statistical Package for Social Sciences 12.0 for
Windows.
All experiments were performed in accordance with
national laws (German law on Protection of Animals) and
the principles of laboratory animal care (NIH publication
No. 86-23, revised 1985). None of the animals died during
the experiment.
Results
Spontaneous motor activity 4–9 days after the end
of TaClo administration
Distance travelled (Data not shown)
With regard to the distance travelled no statistically sig-
niﬁcant differences between the groups were found
(F2,29 = 1.2; p[0.05).
Spontaneous nocturnal motor activity 9 months
after the end of TaClo administration
Separate analysis for each 1-h interval
Distance travelled (Fig. 1a) In the 1-h interval ending at
midnight, the three groups differed with regard to the
distance travelled (F2,26 = 8.89; p\0.01). Post-hoc
analysis showed that the group treated with 0.2 mg/kg
TaClo displayed a signiﬁcant increase in activity compared
to both the other TaClo group (0.4 mg/kg) and the saline
group (p\0.01). In the interval ending at 4 a.m., the
groups differed in their activity (F2,26 = 5.45; p\0.05).
The TaClo-0.4 group showed signiﬁcantly less activity
than the TaClo-0.2 (Student–Newman–Keuls test,
p\0.01) and the saline groups (p\0.01). The remaining
comparisons failed to reach signiﬁcance.
Stereotype time (Fig. 2a) The three groups differed in the
interval ending at midnight (F2,26 = 5.98; p\0.01). Post-
hoc analysis revealed that the TaClo-0.2 group spent more
time with stereotype movements than the control group
(p\0.05) and the TaClo-0.4 group (p\0.05). Differ-
ences between groups were also found in the 1-h intervals
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123ending at 4 a.m. (F2,26 = 6.17, p\0.05) and 5 a.m.
(F2,26 = 5.27, p\0.05). The TaClo-0.4 group showed a
signiﬁcantly reduced stereotype time compared to the other
groups. (Student–Newman–Keuls test; at 4 a.m.: TaClo-0.4
vs. saline p\0.01, TaClo-0.4 vs. TaClo-0.2 p\0.05;
at 5 a.m.: TaClo-0.4 vs. saline p\0.05, TaClo-0.4 vs.
TaClo-0.2 p\0.05). The other comparisons failed to reach
signiﬁcance.
Burst of stereotype movement (Fig. 3a) A difference
betweengroupswasobservedintheintervalendingat10 p.m.
(F2,26 = 6.3, p\0.01), the TaClo-0.4 group showed signiﬁ-
cantly fewer bursts than the saline group (p\0.01) and the
TaClo-0.2 group (p\0.05). A group difference at midnight
(F2,26 = 5.75, p\0.01) was characterised by a signiﬁcant
increase in bursts in the TaClo-0.2 group compared to the
saline (p\0.01) and TaClo-0.4 groups (p\0.05).
Analysis for a total of 10 h
Distance travelled (Fig. 1b) A signiﬁcant difference
between the groups was observed (F2,26 = 4.71, p\0.05).
Post-hoc analysis using Student–Newman–Keuls test
showed that the TaClo-0.2 rats walked more than those of
the saline (p\0.05) and TaClo-0.4 groups (p\0.05).
Stereotype time (Fig. 2b) The time spent with stereotype
movements differed between the groups (F2,26 = 6.38,
p\0.01). Post-hoc analysis revealed that the TaClo-0.4
group spent less time with stereotype movements than both
the control group (p[0.05) and the TaClo-0.2 group
(p\0.01).
Burst of stereotype movements (Fig. 3b) The number of
stereotype movements differed between the groups
(F2,26 = 5.43, p\0.01) with the TaClo-0.4 group dis-
playing signiﬁcantly fewer movements than the TaClo-0.2
group (p\0.01).
Discussion
The aim of the present study was to investigate the long-
term effects of oral administration of the neurotoxin TaClo
on the spontaneous nocturnal activity of rats. Previous
studies have shown that TaClo is neurotoxic to the dopa-
minergic system (for review see Riederer et al. 2002) and
induces changes of the motor behaviour of rats (Heim and
Sontag 1997; Sontag et al. 1995). In these studies, how-
ever, TaClo was injected intraperitoneally, while the neu-
rotoxin was administered orally in the present study. This
approach was used against the background of previous
studies suggesting that the pathogenesis of Parkinson’s
disease begins in the enteric nervous system and is induced
by an unknown pathogenic factor which passes the gas-
trointestinal mucosal barrier (Braak et al. 2003). TaClo
might be such a factor causing neurodegeneration follow-
ing oral administration.
The present study has demonstrated for the ﬁrst time that
oral TaClo administration affects the spontaneous motor
Fig. 1 Distance travelled by the
rats 9 months after the end of
oral TaClo administration
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123activity of rats during the night. The rats treated with
0.2 mg/kg of TaClo walked longer distances than both the
control animals and the rats treated with 0.4 mg/kg of
TaClo (Fig. 1b). In addition, only the TaClo-0.2 group
showed an activity peak around midnight (Fig. 1a). This
data shows that the treatment of rats with TaClo-0.2 over
7 weeks increases the distance travelled and changes the
nocturnal activity pattern in rats. These results refer to
locomotor activity. Non-locomotor activities such as ste-
reotype movements were also shown to be altered fol-
lowing TaClo administration (Figs. 2a, 3a). The TaClo-0.4
group spent signiﬁcantly less time with stereotype move-
ments and the burst of stereotype movements was reduced,
indicating a general reduction of motor activity.
These results show an increase in motor activity in the
low-dose TaClo group and a decrease in the high-dose
group at 9 months after the end of the treatment. However,
a previous study (Sontag et al. 1995) showed a reduced
activity in female rats 9 weeks after the end of a 7-week
treatment with TaClo (0.2 mg/kg intraperitoneally). One
explanation for the different results could be the gender of
the rats used since sex-related differences in the metabo-
lism of trichlorethylene (a precursor of TaClo) in the liver
have been found (Elfarra et al. 1998). However, it is more
likely that the way of TaClo administration contributes to
these differences. Previous data indicate a slow neurode-
generative effect in rats following the intraperitoneal
treatment with TaClo. In a previous study (Heim and
Sontag 1997), the spontaneous locomotor activity as
measured for 1 h in the morning was increased 4–9 days
after a daily injection of TaClo-0.2 over 7 weeks. How-
ever, 9 months after TaClo administration this difference
could not be observed. It has been suggested that dopamine
receptors are upregulated as an acute response to the
degenerative process induced by TaClo. In the present
study, an increase in locomotor activity was not observed
4–9 days after the end of treatment. This suggests that
orally administered TaClo does not induce neurodegener-
ative effects at this point in time. However, 9 months later
the total nocturnal activity is decreased in the high-dose
TaClo group indicating reduced dopaminergic functioning.
Both oral and intraperitoneal administration appears to
have similar behavioural effects on the motor system of
rats, with a later onset following oral administration.
The TaClo-0.4 group showed no marked differences to the
control group. However, on the basis of the data of the
TaClo-0.2 group one can conclude that oral administration
was effective and caused neurodegenerative processes
producing reduced motor activity later on (Heim and
Sontag 1997). It is possible that the TaClo-0.4 group had
developed reduced motor activity, i.e. the TaClo-induced
degeneration developed faster in the TaClo-0.4 group than
in the TaClo-0.2 group. The difference between the two
TaClo groups suggests therefore a dose-dependent effect of
TaClo.
Furthermore, not only the amount of motor activity is
affected but also the pattern of activity (Figs. 1a, 2a, 3a).
This might hint to a disturbed sleeping pattern which can
also be observed Parkinson’s disease (Partinen 1997).
Stereotactically administered TaClo has been shown to
induce the release of both dopamine and serotonin (Gerlach
et al. 1998). In addition, it has been shown that TaClo
reduces serotonin uptake in the human serotonergic cell
line JAR (Bringmann et al. 2000). Since serotonin is
Fig. 2 Time spent with
stereotype movements in rats
9 months after the end of oral
TaClo administration
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123known to be involved in the regulation of sleep, the present
ﬁndings could indicate that TaClo affects serotonin-related
behaviours in rats.
In summary, the present study has demonstrated that
TaClo administered orally induces alterations in sponta-
neous motor behaviour which are similar to those observed
following intraperitoneal administration. These ﬁndings
suggest that TaClo can induce neurodegeneration follow-
ing both intraperitoneal and oral administration. Oral
administration of TaClo in rats may be useful in investi-
gating the hypothesis by Braak et al. (2002) that an
unknown pathogenic factor crossing the mucosa barrier can
induce neurodegenerative processes which eventually
affect the entire brain.
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